A sensitive epitope-blocking ELISA for the detection of Chikungunya virus-specific antibodies in patients
Introduction
Chikungunya virus (CHIKV), the etiological agent of Chikungunya fever (CHIKF), belongs to the family Togaviridae and genus Alphavirus. CHIKV was first isolated in 1952 during an outbreak in Tanzania, East Africa (Robinson, 1955). Since then, CHIKV has caused sporadic epidemics of rheumatic disease though its prevalence has increased dramatically in recent years (Powers and Logue, 2007). Between 2004 and 2011, CHIKV was responsible for a massive outbreak at an estimated 1.4–6.5 million infections, with imported cases reported in over 40 countries (Suhrbier et al., 2012). Geographical expansion of the Aedes albopictus mosquito's distribution has allowed for the first autochthonous CHIKV infections in Italy and France, in 2007 and 2010, respectively (Rezza et al., 2007, Angelini et al., 2008, Grandadam et al., 2011). The increase in international travel has also seen the virus spread to previously unaffected countries such as the USA, the Caribbean and Australasia (Schwartz and Albert, 2010, Gibney et al., 2011, Viennet et al., 2013, Higgs, 2014, Mansuy et al., 2014).
CHIKF is characterized by an abrupt onset of fever, headache, myalgia, fatigue, nausea, rashes (usually maculopapular) and severe polyarthralgia, which can persist from weeks to months (Robinson, 1955, Brighton et al., 1983, Hoarau et al., 2010). The re-emergence of CHIKV has seen it be associated with severe disease manifestations and mortality, primarily in elderly patients with co-morbidities and the very young (Mavalankar et al., 2008, Economopoulou et al., 2009, Tandale et al., 2009, Jaffar-Bandjee et al., 2010). Furthermore, mother-to-child transmission was also observed with about half the infected neonates developing serious disease outcomes such as haemorrhage, disseminated intravascular coagulation and/or cardiac and neurological complications, with the latter often leading to permanent disabilities (Rampal et al., 2007, Gerardin et al., 2008, Suhrbier et al., 2012). The treatment of rheumatic disease caused by CHIKV currently involves the use of painkillers and/or non-steroidal anti-inflammatory drugs. Presently, there are no licensed human vaccines available although CHIKV vaccines are in development (Akahata et al., 2010, Wang et al., 2011, Brandler et al., 2013, Metz et al., 2013, Powers, 2014).
The clinical profile of CHIKF is similar to that of several other infections such as dengue fever, malaria and a host of closely-related arthralgic alphaviral diseases (Carey, 1971, Sergon et al., 2007, Suhrbier et al., 2012, Roth et al., 2014). Co-infection of CHIKV with dengue virus and other tropical arboviruses that cause non-specific symptoms similar to CHIKF have also been reported, highlighting the requirement of definitive diagnostic tests to assist clinicians with treatment options as well as to inaugurate appropriate public health measures (Vazeille et al., 2010, Kumar et al., 2012, Baba et al., 2013).
During early stages of the infection when antibody responses have not been generated, virus culture and/or PCR-based techniques are typically utilized for the detection of CHIKV. However, blood samples must be taken during the viraemic period, which typically lasts only 5–7 days (Edwards et al., 2007, Laurent et al., 2007, Santhosh et al., 2007). Moreover, this narrow window of opportunity for nucleic acid detection often starts prior to the onset of symptoms, thus further limiting the opportunity of obtaining viraemic patient samples for virus culture or PCR. Although the above-mentioned techniques are still considered gold standards for diagnosing CHIKV, both techniques require specialized facilities or equipment, as well as technical expertise to perform, which are too costly and impractical for widespread use.
In later phases of the illness (>1–2 weeks post-infection), IgM antibody-capture ELISAs (MAC-ELISAs) are the most commonly used tests for laboratory-based diagnoses. Other serological tests available include hemagglutination inhibition (HI), indirect ELISAs and virus-neutralization assays (Adesina and Odelola, 1991, Tiwari et al., 2009, Sam et al., 2011). However, most existing MAC-ELISA and HI tests are poorly established and lack credibility, in terms of specificity, due to the high possibility of false-positive results from cross-reactivity with other closely-related alphaviruses such as Ross river virus (RRV), Barmah Forest virus (BFV) and Sindbis virus (Niedrig et al., 2009, Rianthavorn et al., 2010, Blacksell et al., 2011, Kosasih et al., 2012, Reddy et al., 2012). Plaque-reduction virus-neutralization tests (PRNTs) are currently recommended by the world health organisation (WHO) for serological detection of CHIKV antibodies in human. However, these assays are not only labour-intensive, but also require access to bio-containment facilities due to the handling of infectious virus, rendering them impractical for rapid and high-throughput diagnostics.
According to the World Health Organisation, the ideal test should be rapid, specific, sensitive, cost-effective, user-friendly for lesser skilled personnel, and robust in different climatic conditions. More importantly, the test should also be equipment-free (in terms of dependence on electricity) and easily accessible to those who need it (Urdea et al., 2006). Herein we report the use of a monoclonal antibody (mAb) to the viral E2 protein and recombinant virus-like particles (VLPs), produced in insect cells (Metz et al., 2013), in an epitope-blocking ELISA (EB-ELISA) for the sensitive and specific detection of anti-CHIKV antibodies in human sera. The use of a CHIKV-specific mAb in the assay has allowed for the development of a highly-specific diagnostic test for CHIKV that should not produce false-positive results with closely-related alphaviruses, as well as other co-circulating arboviruses such as dengue virus. Furthermore, the utilization of stably-expressed non-infectious recombinant VLPs as the coating antigen will enable the assay to be performed safely without requirements of biosafety containment.
Section snippets
Cell and virus culture
C6/36 (A. albopictus mosquito) cells were propagated in RPMI 1640 supplemented with 2% fetal bovine serum (FBS, Gibco, Life Technologies). Cultures were passaged by dissociating the cell monolayer from tissue culture flasks (Greiner Bio-One) with trypsin/PBS and were incubated at 28 °C. African green monkey kidney epithelial-derived Vero-E6 cells were cultured in DMEM (Gibco, Life Technologies) supplemented with 10% FBS. The mammalian cells were passaged by dissociating the surface monolayer
Detection of CHIKV by E2-specific mAbs
Preliminary testing was carried out to determine the affinities of five biotin-labelled CHIKV E2-specific mAbs, designated 1.3A2, 4.6F5, 4.10C12, 5.2B2 and 5.2H8, against the two coating antigens used for this study – CHIKV VLPs and live, infectious virions – in an indirect ELISA. Biotinylated mAb 1.3A2, at its optimal sub-saturating concentration of 1.25 μg/mL, showed the strongest interaction with both the CHIKV VLPs and infectious virions, with OD405 nm readings of >1.0 (results not shown).
Discussion
Epitope-blocking ELISAs have been successfully used for the sensitive and specific detection of serum antibodies to a variety of viral pathogens, including RRV, West Nile virus and influenza (Hall et al., 1995, Blitvich et al., 2003, Oliveira et al., 2006, Lorono-Pino et al., 2009, Prabakaran et al., 2009, Sotelo et al., 2011). This study describes the use of a mAb that recognizes an epitope on the CHIKV E2 protein in an EB-ELISA to detect CHIKV-specific antibodies in clinical specimens.
Sixty
Conclusions
The EB-ELISA for CHIKV diagnosis described here represents a rapid, simple, highly-sensitive and specific assay that is also cost-effective and safe. These attributes potentially meet the criteria set by the WHO for an ideal diagnostic test for CHIKV and may be utilized as a rapid front-line screening assay for the serodiagnosis of CHIKF. Furthermore, the platform's robustness will enable it to be used in harsher environments as a point-of-care test.
Acknowledgements
We would like to thank the study participants and healthy volunteers for their contribution, the research staff from Communicable Disease Centre/Tan Tock Seng Hospital, namely, Meng-Li Teo for her assistance in blood sample preparation, Clement Kan, Amy Chan and Mar-Kyaw Win for their help in patient enrolment, study coordination and data entry, as well as the clinical staff of Communicable Disease Centre/Tan Tock Seng Hospital for their efforts in patient enrolment and care. The CHIKV VLPs
References (58)
- et al.
A recombinant measles vaccine expressing Chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with Chikungunya virus
Vaccine
(2013) - et al.
Molecular diagnosis and analysis of Chikungunya virus
J. Clin. Virol.
(2007) - et al.
Neutralizing monoclonal antibodies to the E2 protein of Chikungunya virus protects against disease in a mouse model
Clin. Immunol.
(2013) - et al.
Immunodominant epitopes on the NS1 protein of MVE and KUN viruses serve as targets for a blocking ELISA to detect virus-specific antibodies in sentinel animal serum
J. Virol. Methods
(1995) - et al.
International diagnostic accuracy study for the serological detection of Chikungunya virus infection
Clin. Microbiol. Infect.
(2009) - et al.
Infection with Chikungunya virus in Italy: an outbreak in a temperate region
Lancet
(2007) An epidemic of virus disease in Southern Province, Tanganyika territory, in 1952–1953. I. Clinical features
Trans. R. Soc. Trop. Med. Hyg.
(1955)- et al.
Development and evaluation of SYBR Green I-based one-step real-time RT-PCR assay for detection and quantification of Chikungunya virus
J. Clin. Virol.
(2007) - et al.
Development and evaluation of a new epitope-blocking ELISA for universal detection of antibodies to West Nile virus
J. Virol. Methods
(2011) - et al.
Systemic involvements and fatalities during Chikungunya epidemic in India, 2006
J. Clin. Virol.
(2009)
Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus
Vaccine
A complex adenovirus vaccine against Chikungunya virus provides complete protection against viraemia and arthritis
Vaccine
Ecological distribution of Chikungunya haemagglutination inhibition antibodies in human and domestic animals in Nigeria
Trop. Geogr. Med.
A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection
Nat. Med.
Chikungunya epidemic outbreak in Emilia-Romagna (Italy) during summer 2007
Parassitologia
Evidence of arbovirus co-infection in suspected febrile malaria and typhoid patients in Nigeria
J. Infect. Dev. Countr.
Chikungunya virus strains. Reunion Island outbreak
Emerg. Infect. Dis.
Poor diagnostic accuracy of commercial antibody-based assays for the diagnosis of acute Chikungunya infection
Clin. Vaccine Immunol.
Epitope-blocking enzyme-linked immunosorbent assays for detection of west nile virus antibodies in domestic mammals
J. Clin. Microbiol.
Chikungunya virus infection. A retrospective study of 107 cases
S. Afr. Med. J.
Chikungunya and dengue: a case of mistaken identity?
J. Hist. Med. Allied Sci.
Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor
J. Infect. Dis.
In situ reactions of monoclonal antibodies with a viable mutant of Murray Valley encephalitis virus reveal an absence of dimeric NS1 protein
J. Gen. Virol.
Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005–2006 outbreak on Reunion
Epidemiol. Infect.
Multidisciplinary prospective study of mother-to-child Chikungunya virus infections on the island of La Reunion
PLoS Med.
Chikungunya fever in the United States: a fifteen year review of cases
Clin. Infect. Dis.
Chikungunya virus, southeastern France
Emerg. Infect. Dis.
Type-specific monoclonal antibodies produced to proteins of Murray Valley encephalitis virus
Immunol. Cell Biol.
Chikungunya virus: a major emerging threat
Vector Borne Zoonotic Dis.
Cited by (9)
Diagnostics and laboratory techniques
2018, Chikungunya and Zika Viruses: Global Emerging Health ThreatsDevelopment of a Blocking ELISA Method for Detection of Getah Virus Antibodies in Horse Sera
2023, Journal of Bacteriology and VirologyDiagnostic accuracy of serological tests for the diagnosis of Chikungunya virus infection: A systematic review and meta-analysis
2022, PLoS Neglected Tropical DiseasesBeyond fever and pain: Diagnostic methods for chikungunya virus
2019, Journal of Clinical MicrobiologyVaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice
2019, PLoS Neglected Tropical Diseases